Drug shown to slow progress of motor neurone disease
An experimental drug for motor neurone disease has shown signs of slowing the progress of the devastating illness in a landmark trial. The results, published in the New England Journal of Medicine, provide fresh hope after a phasethree trial of the same drug had previously failed to make a meaningful difference to patient outcomes after six months of treatment. The latest results suggest that when patients continued taking the Biogen drug Tofersen for another six months they experienced better mobility and lung function, with some reporting remarkable outcomes.
Global Report
en-gb
2022-09-30T07:00:00.0000000Z
2022-09-30T07:00:00.0000000Z
https://theguardianweekly.pressreader.com/article/281767043097754
Guardian/Observer